Analystreport

Blueprint Medicines Co. (NASDAQ: BPMC) had its price target lowered by analysts at Wedbush from $136.00 to $130.00. They now have an "outperform" rating on the stoc

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com